IQ Webinar: Nanomedicine Development: Physicochemical Characterization Consideration
Presented by the Nanomaterial and Nanotechnology Working Group
Sponsored by the Drug Product Leadership Group
SPEAKER: Jeffrey Clogston, Nanotechnology Characterization Laboratory
The National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL) conducts preclinical characterization including physicochemical (analytical), in vitro, and in vivo of nanoparticles intended as cancer therapeutics and diagnostics. This presentation will highlight the characterization parameters, methods, and considerations related to the physicochemical characterization of nanoparticle delivery systems from the testing of more than 450 nanotechnology-based candidate cancer treatments and diagnostics, and are based on the characterization aspects found in the chemistry, manufacturing, and controls (CMC) section in the FDA's industry guidance document for liposome drug products.
Furthermore, the current gaps and needs in the physicochemical characterization of nanoparticle delivery systems will be discussed.